Ametantrone is primarily researched for its potential in cancer treatment due to its ability to interfere with DNA replication and cell division. It has shown activity against certain types of tumors, including breast cancer and acute leukemia, particularly in preclinical studies. The compound is being explored for its efficacy in chemotherapy regimens, especially in cases where other treatments have failed. Additionally, its mechanism of action, which involves intercalating into DNA and inhibiting topoisomerase II, makes it a candidate for combination therapies with other anticancer agents. Research is ongoing to determine its full therapeutic potential and to optimize its use in clinical settings. It should be handled with care due to potential severe side effects, such as cardiotoxicity and immunosuppression.